Related Experiment Video
Updated: Aug 10, 2025
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
Comprehensive Analysis of KCNJ14 Potassium Channel as a Biomarker for Cancer Progression and Development
1Department of Biochemistry, College of Medicine, Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
Abstract:
Cancer is a global epidemic that has affected millions of lives. Discovering novel cancer targets is widely viewed as a key step in developing more effective therapies for cancer and other fatal illnesses. More recently, potassium (K+) channels have been studied as a potential biological target for the creation of cancer treatments. Potassium Inwardly Rectifying Channel Subfamily J Member 14 (KCNJ14) is one of the cancer genome's least investigated genes. This study conducted a comprehensive examination of the relationships between KCNJ14 gene expression analysis, survival, RNA modification, immunotherapy participation, and cancer stemness using several databases. KCNJ14 was shown to be dysregulated in a variety of cancers, including lung, intestinal, head and neck, oesophageal, and stomach. Additionally, KCNJ14 was shown to be linked to RNA and DNA stemness in 18 and 15 different tumour types, respectively. Moreover, KCNJ14 was discovered to be positively linked with immunological checkpoints and suppressor cells and to have a negative immunophenoscore (IPS). KCNJ14 was linked to tumour mutation burden (TMB), microsatellite instability (MSI), neoantigen (NEO), and programmed death ligand 1 (PD-L1); all four are potential targets for immunotherapies. In addition, a favourable relationship between genomic-instability markers such as heterozygosity (LOH), homologous recombination deficiency (HRD), and mutant-allele tumour heterogeneity (MATH) was demonstrated with KCNJ14. Based on these novel findings, KCNJ14 may be a useful independent prognostic biomarker for a range of cancers.
Insights
The KCNJ14 gene is dysregulated in multiple cancers and linked to cancer stemness and immune evasion. This gene may serve as a novel prognostic biomarker for various cancers, aiding in developing new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Cancer remains a global health challenge, necessitating the discovery of novel therapeutic targets.
- Potassium (K+) channels are emerging as potential targets for cancer treatment development.
- The KCNJ14 gene, part of the cancer genome, has been underexplored as a therapeutic target.
Purpose of the Study:
- To comprehensively investigate the role of KCNJ14 in cancer.
- To analyze the associations between KCNJ14 gene expression, patient survival, RNA modification, immunotherapy response, and cancer stemness.
- To evaluate KCNJ14 as a potential prognostic biomarker across various cancer types.
Main Methods:
- Utilized multiple public databases for comprehensive gene expression analysis.
- Correlated KCNJ14 expression with survival data, RNA modifications, and cancer stemness indicators.
- Assessed the relationship between KCNJ14 and markers of immune infiltration, tumor mutation burden (TMB), microsatellite instability (MSI), and neoantigens (NEO).
Main Results:
- KCNJ14 dysregulation was observed in lung, intestinal, head and neck, oesophageal, and stomach cancers.
- KCNJ14 expression correlated with RNA and DNA stemness in numerous tumor types.
- KCNJ14 showed positive associations with immune checkpoints and suppressor cells, and negative correlation with immunophenoscore (IPS).
- KCNJ14 was linked to TMB, MSI, NEO, and programmed death ligand 1 (PD-L1), key immunotherapy targets.
- Favorable associations were found between KCNJ14 and genomic instability markers like LOH, HRD, and MATH.
Conclusions:
- KCNJ14 is significantly dysregulated across a spectrum of cancers.
- KCNJ14 plays a role in cancer stemness and influences the tumor immune microenvironment.
- KCNJ14 demonstrates potential as an independent prognostic biomarker for diverse cancers, offering new avenues for therapeutic strategies.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:24Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:26Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...